Immunocore Announces Randomization Of The First Patient In The PRISM-MEL-301 Trial Of Brenetafusp (IMC-F106C; PRAME-A02), In Combination With Nivolumab, In First-line Advanced Or Metastatic Cutaneous Melanoma
Portfolio Pulse from Benzinga Newsdesk
Immunocore has announced the randomization of the first patient in the PRISM-MEL-301 trial of Brenetafusp (IMC-F106C; PRAME-A02) in combination with Nivolumab for first-line advanced or metastatic cutaneous melanoma.
June 18, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunocore has started patient randomization in its PRISM-MEL-301 trial for Brenetafusp in combination with Nivolumab, targeting advanced melanoma.
The initiation of patient randomization in a clinical trial is a significant milestone for Immunocore, indicating progress in their drug development pipeline. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100